Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ranibizumab Launch - Midas Pharma is the Marketing Authorisation Holder (MAH) of a Biosimilar
Details : Ranivisio (ranibizumab) is a VEGF-A inhibitor, which is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema.
Product Name : Ranivisio
Product Type : Antibody
Upfront Cash : Inapplicable
November 10, 2023
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EMA CHMP Recommends Grant of Marketing Authorization of Ranibizumab Biosimilar
Details : The active substance of Ranivisio is ranibizumab, a monoclonal antibody fragment (ATC code: S01LA04) which modulates angiogenesis by inhibiting vascular endothelial growth factor A. Ranivisio is a biosimilar medicinal product.
Product Name : Ranivisio
Product Type : Antibody
Upfront Cash : Inapplicable
June 23, 2022
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
